Researchers are advancing a targeted nasal delivery method for amifostine to protect healthy tissue during pancreatic cancer radiation therapy.

Keros Therapeutics has discontinued development of cibotercept (KER-012) for pulmonary arterial hypertension after observing dose-dependent pericardial effusions in the TROPOS Phase 2 trial.

A study of 208 patients with early-stage breast cancer found a low 3.5% rate of cosmetic deterioration three years after hypofractionated partial breast irradiation (PBI).

Cocrystal Pharma's broad-spectrum antiviral CC-42344 demonstrated inhibitory activity against the highly pathogenic avian influenza A (H5N1) PB2 protein in recently completed in vitro studies.

A Delaware federal judge ruled that Liquidia Corp. waited too long to raise two specific invalidity theories in United Therapeutics Corp.'s 2023 patent lawsuit over competing lung disease treatments.

GC Biopharma's Phase 3 clinical trial results for Hunterase (idursulfase beta) in Hunter Syndrome patients have been published in Genetics in Medicine, demonstrating significant improvements in functional mobility and metabolic markers.

Genentech's Phase III REGENCY trial demonstrates that Gazyva plus standard therapy achieved 46.4% complete renal response in lupus nephritis patients compared to 33.1% with standard therapy alone.

The Phase II NeoCOAST-2 trial evaluated three novel pre-surgical treatment combinations for resectable non-small cell lung cancer, with the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) arm achieving the highest pathological complete response rate at 35.2%.

China's National Medical Products Administration approved trastuzumab deruxtecan for HER2-positive breast cancer patients who received prior anti-HER2 therapies, based on DESTINY-Breast03 trial showing 72% reduction in disease progression risk.

Leads Biolabs' LBL-024, a first-in-class PD-L1/4-1BB bispecific antibody, achieved a 75% overall response rate in 52 patients with advanced extrapulmonary neuroendocrine carcinoma when combined with chemotherapy.

Radiopharm Theranostics' imaging molecule RAD 101 successfully detected brain metastases in all 22 patients during an observational trial, including both treatment-naïve and previously treated individuals.

Phase I trial results demonstrate CONV01-α combined with 177Lu-PSMA-I&T achieved 29.8-month median overall survival in metastatic castration-resistant prostate cancer patients, doubling VISION trial outcomes.

Creative Medical Technology's CELZ-201 demonstrated significant reduction in insulin dependency and stable HbA1c levels in late-stage Type 2 diabetes patients over one year of treatment.

The phase II ALNEO trial achieved its primary endpoint, demonstrating a 46% major pathological response rate with neoadjuvant alectinib in 33 patients with potentially resectable stage III ALK-positive NSCLC.

Eli Lilly's investigational folate receptor alpha-targeting ADC LY4170156 demonstrated a 55% overall response rate at the recommended Phase 2 dose in heavily pre-treated platinum-resistant ovarian cancer patients.

Outlook Therapeutics has commercially launched LYTENAVA™ (bevacizumab gamma) in Germany and the UK, marking the first and only approved ophthalmic formulation of bevacizumab for wet AMD treatment in Europe.

Novartis' NATALEE trial subgroup analysis reveals Kisqali plus endocrine therapy reduced invasive disease risk by 33% in pre-menopausal early breast cancer patients at 44.2 months median follow-up.

Merus N.V.'s petosemtamab receives FDA Breakthrough Therapy designation for first-line treatment of PD-L1 positive head and neck cancer when combined with pembrolizumab.

A multicenter study of 580 kidney transplant patients demonstrates AlloSeq cfDNA's high accuracy in detecting allograft rejection, achieving an AUC of 0.758.

Novel capsid inhibitor lenacapavir demonstrates significant antiviral activity in phase 3 trial, with 88% of patients experiencing viral load reduction within 15 days of treatment.